Why Gilead's Coronavirus Drug Could Be A Mega Blockbuster: Analyst

Why Gilead's Coronavirus Drug Could Be A Mega Blockbuster: Analyst

Gilead's coronavirus drug, remdesivir, could capture nearly $8 billion in 2022 sales, an analyst said Wednesday as he upgraded GILD stock. He sees promise for Gilead in cancer drugs.